0.3001
price down icon1.96%   -0.006
after-market Handel nachbörslich: .30 -0.000100 -0.03%
loading
Schlusskurs vom Vortag:
$0.3061
Offen:
$0.3062
24-Stunden-Volumen:
466.80K
Relative Volume:
0.36
Marktkapitalisierung:
$17.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-41.95M
KGV:
-0.3616
EPS:
-0.83
Netto-Cashflow:
$-38.34M
1W Leistung:
-4.94%
1M Leistung:
-13.37%
6M Leistung:
-52.81%
1J Leistung:
-92.63%
1-Tages-Spanne:
Value
$0.2958
$0.3099
1-Wochen-Bereich:
Value
$0.2958
$0.3214
52-Wochen-Spanne:
Value
$0.221
$4.33

Elevation Oncology Inc Stock (ELEV) Company Profile

Name
Firmenname
Elevation Oncology Inc
Name
Telefon
(716) 371-1125
Name
Adresse
101 FEDERAL STREET, BOSTON
Name
Mitarbeiter
34
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-05
Name
Neueste SEC-Einreichungen
Name
ELEV's Discussions on Twitter

Vergleichen Sie ELEV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ELEV
Elevation Oncology Inc
0.3001 18.70M 0 -41.95M -38.34M -0.83
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-24 Herabstufung Stephens Overweight → Equal-Weight
2025-03-21 Herabstufung Citizens JMP Mkt Outperform → Mkt Perform
2025-03-21 Herabstufung Leerink Partners Outperform → Market Perform
2025-03-21 Herabstufung Piper Sandler Overweight → Neutral
2025-01-03 Eingeleitet William Blair Outperform
2024-05-31 Eingeleitet Piper Sandler Overweight
2024-05-14 Eingeleitet Stephens Overweight
2024-03-01 Eingeleitet JMP Securities Mkt Outperform
2023-05-30 Hochstufung SVB Securities Market Perform → Outperform
2021-12-23 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Elevation Oncology Inc Aktie (ELEV) Neueste Nachrichten

pulisher
May 17, 2025

Elevation Oncology Reports Q1 2025 Financial Results - TipRanks

May 17, 2025
pulisher
May 16, 2025

William Blair Remains a Buy on Elevation Oncology (ELEV) - The Globe and Mail

May 16, 2025
pulisher
May 15, 2025

Elevation Oncology Explores Strategic Alternatives - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Elevation Oncology Advances Novel HER3 ADC Program While Securing Cash Runway Through 2026 - Stock Titan

May 15, 2025
pulisher
May 15, 2025

Elevation Oncology, Inc. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 14, 2025

Allogene's Q1 Earnings In Line With Estimates, Sales Nil - Barchart.com

May 14, 2025
pulisher
May 09, 2025

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% On '25 View Cut - Barchart.com

May 09, 2025
pulisher
May 09, 2025

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut - Yahoo Finance

May 09, 2025
pulisher
May 08, 2025

Elevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Recommendation of “Hold” from Brokerages - Defense World

May 08, 2025
pulisher
May 07, 2025

Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook - Zacks Investment Research

May 07, 2025
pulisher
May 06, 2025

JPMorgan Chase & Co. Purchases 119,041 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

May 06, 2025
pulisher
May 02, 2025

Geode Capital Management LLC Grows Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

May 02, 2025
pulisher
May 01, 2025

Renaissance Technologies LLC Sells 182,673 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

May 01, 2025
pulisher
Apr 29, 2025

William Blair Reaffirms Their Buy Rating on Elevation Oncology (ELEV) - The Globe and Mail

Apr 29, 2025
pulisher
Apr 29, 2025

Elevation Oncology Inc Inc. (ELEV) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com

Apr 29, 2025
pulisher
Apr 28, 2025

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

Apr 28, 2025
pulisher
Apr 28, 2025

Elevation Oncology Inc (ELEV)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

Elevation Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView

Apr 28, 2025
pulisher
Apr 25, 2025

Elevation Oncology reveals promising ADC data for solid tumors - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Elevation Oncology reveals promising ADC data for solid tumors By Investing.com - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Breakthrough Cancer Drug EO-1022 Outperforms Existing HER3 Therapies in Stability and Anti-Tumor Activity - Stock Titan

Apr 25, 2025
pulisher
Apr 24, 2025

Adversity is less terrifying than hope: Elevation Oncology Inc (ELEV) - Sete News

Apr 24, 2025
pulisher
Apr 24, 2025

Elevation Oncology (ELEV) to Release Quarterly Earnings on Thursday - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

Market Recap Check: Elevation Oncology Inc (ELEV)’s Negative Finish at 0.37, Up/Down -1.61 - DWinneX

Apr 23, 2025
pulisher
Apr 22, 2025

Potential Price Increase for Elevation Oncology Inc (ELEV) After Recent Insider Activity - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Are Elevation Oncology Inc’shares a good deal? - uspostnews.com

Apr 22, 2025
pulisher
Apr 21, 2025

Elevation Oncology Inc (ELEV): What Makes The Stock Good? - Marketing Sentinel

Apr 21, 2025
pulisher
Apr 18, 2025

GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech - BioPharma Dive

Apr 18, 2025
pulisher
Apr 18, 2025

Elevation mulls strategic alternatives, including closure, amid activist pressure - PharmaLive

Apr 18, 2025
pulisher
Apr 18, 2025

Elevation Mulls Strategic Alternatives, Including Closure, Amid Activist Pressure - BioSpace

Apr 18, 2025
pulisher
Apr 17, 2025

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com

Apr 17, 2025
pulisher
Apr 17, 2025

Elevation is latest biotech to face activist investor demands to wind down - Fierce Biotech

Apr 17, 2025
pulisher
Apr 16, 2025

Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) PT at $3.39 - Defense World

Apr 16, 2025
pulisher
Apr 14, 2025

Rare NRG1 Fusion Market to Reach New Heights in Growth by 2034, - openPR.com

Apr 14, 2025
pulisher
Apr 11, 2025

Fierce Biotech Layoff Tracker 2025: Pfizer sells site, cuts staff; Opthea reduces workforce by 65% - Fierce Biotech

Apr 11, 2025
pulisher
Apr 08, 2025

Trading Day Review: Elevation Oncology Inc (ELEV) Loses Momentum, Closing at 0.25 - DWinneX

Apr 08, 2025
pulisher
Apr 04, 2025

Elevation Oncology opts for early term loan repayment By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Elevation Oncology opts for early term loan repayment - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Elevation Oncology IncTo Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022SEC Filing - MarketScreener

Apr 04, 2025
pulisher
Apr 03, 2025

Elevation Oncology stock hits 52-week low at $0.24 By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Takes $36,000 Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Elevation Oncology’s Chief Medical Officer Steps Down - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

What is Elevation Oncology Inc (ELEV) Stock Return on Shareholders’ Capital? - Sete News

Apr 01, 2025

Finanzdaten der Elevation Oncology Inc-Aktie (ELEV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):